MIRA INFORM REPORT

 

 

Report No. :

302618

Report Date :

13.01.2015

 

IDENTIFICATION DETAILS

 

Name :

PARENTERAL DRUGS (INDIA) LIMITED

 

 

Registered Office :

340, Laxmi Plaza, Laxmi Industrial Estate, New Link Road, Andheri (West), Mumbai – 400053, Maharashtra

 

 

Country :

India

 

 

Financials (as on) :

31.03.2014

 

 

Date of Incorporation :

13.12.1983

 

 

Com. Reg. No.:

11-126481

 

 

Capital Investment / Paid-up Capital :

Rs.  403.542 Millions

 

 

CIN No.:

[Company Identification No.]

L99999MH1983PLC126481

 

 

IEC No.:

Not Available

 

 

TAN No.:

[Tax Deduction & Collection Account No.]

Not Available

 

 

PAN No.:

[Permanent Account No.]

Not Available

 

 

Legal Form :

A Public Limited Liability Company. The Company’s Shares are Listed on the Stock Exchanges.

 

 

Line of Business :

Subject is Involved in research, production and manufacturing of pharmaceutical products like intravenous infusion, tablets, capsules, liquids syrups, injections etc.

 

 

No. of Employees :

Information declined by the management.

 

 

RATING & COMMENTS

 

MIRA’s Rating :

B (30)

 

RATING

STATUS

PROPOSED CREDIT LINE

26-40

B

Capability to overcome financial difficulties seems comparatively below average.

Small

 

 

Status :

Satisfactory

 

 

Payment Behaviour :

Slow but correct

 

 

Litigation :

Exist

 

 

Comments :

Subject is an established company having moderate track.

 

The company has incurred a loss from its operation during 2014.

 

However, trade relations are fair. Business is active. Payments terms are reported to be slow but correct.

 

The company can be considered for business dealings with some cautions.

 

NOTES :

Any query related to this report can be made on e-mail : infodept@mirainform.com while quoting report number, name and date.

 

 

EXTERNAL AGENCY RATING

 

Rating Agency Name

CARE

Rating

Long Term Bank Facilities: B +

Rating Explanation

Have high risk of default.

Date

04.09.2013

 

Rating Agency Name

CARE

Rating

Short Term Bank Facilities: A4

Rating Explanation

Have minimal degree of safety and carry very high credit risk. 

Date

04.09.2013

 

 

RBI DEFAULTERS’ LIST STATUS

 

Subject’s name is not enlisted as a defaulter in the publicly available RBI Defaulters’ list.

 

 

EPF (Employee Provident Fund) DEFAULTERS’ LIST STATUS

 

Subject’s name is not enlisted as a defaulter in the publicly available EPF (Employee Provident Fund) Defaulters’ list as of 31-03-2014.

 

 

INFORMATION DENIED

 

Management Non Co-operative (91-731-6652202/6652002

 

 

LOCATIONS

 

Registered Office :

340, Laxmi Plaza, Laxmi Industrial Estate, New Link Road, Andheri (West), Mumbai – 400 053, Maharashtra, India

Tel. No.:

91-22-66943547/ 26304940/ 42762888 / 6652007

Fax No.:

91-22-26333763

E-Mail :

pdpl@pdindia.com

amaragal@pdindia.com

pdpl_mumbai@pdindia.com

Website :

http://www.pdindia.com

Location :

Owned

 

 

Corporate Office and Investors Grievances Centre :

Shree Ganesh Chambers, A.B. Road , Navlakha Crossing, Indore – 452 001 Madhya Pradesh, India

Tel. No.:

91-731-4092000/ 6652000 / 6652001

Fax No.:

91-731-2401052

 

 

Plants

(Manufacturing Location) :

·         Village Asrawad, Post Dudhia, Nemawar Road, Indore – 453331, Madhya Pradesh, India

Tel No.: 91-731-3917834

 

·         Village Sura, Post Suranussi, Jalandhar – 144027, Punjab, India

 

·         Village Bhud, Tehsil Nalagarh, District Solan – 173205, Himachal Pradesh, India

 

·         Honda Industrial Estate Plot No.1, Phase III, Honda, Sattari – 403530, Goa, India

 

 

Overseas Factory 1 :

Old Moka Road, Bell Village, P. O. Box 770, Republic of Mauritius

 

 

Overseas Factory 2 :

ARNA Industrial Estate, Kapchagai, Republic of Kazakhstan

 

 

Overseas Factory 3 :

Located at:

 

·         Nairobi

 

 

DIRECTORS

 

AS ON 31.03.2014

 

Name :

Mr. Manoharlal Gupta

Designation :

Chairman-Cum-Managing Director 

 

 

Name :

Mr. Vinod Kumar Gupta

Designation :

Managing Director

 

 

Name :

Mr. Govind Das Garg

Designation :

Whole Time Director

 

 

Name :

Mr. Anil Mittal

Designation :

Whole Time Director and Chief Executive

 

 

Name :

Mr. Satish Chandra Consul

Designation :

Independent Director

 

 

Name :

Mr. Dharam Pal Khanna

Designation :

Independent Director

 

 

Name :

Mr. Dilip Kumar Panchaity

Designation :

Independent Director

 

 

Name :

Mr. Dilip Kumar Sinha

Designation :

Independent Director

 

 

KEY EXECUTIVES

 

Name :

Ms. Aradhana Kulkarni

Designation :

Company Secretary and Compliance Officer

 

 

SHAREHOLDING PATTERN

 

As on 30.09.2014

 

Category of Shareholder

Total No. of Shares

Total Shareholding as a % of Total No. of Shares

As a % of (A+B)

(A) Shareholding of Promoter and Promoter Group

http://www.bseindia.com/include/images/clear.gif(1) Indian

 

 

http://www.bseindia.com/include/images/clear.gifBodies Corporate

21849243

73.28

http://www.bseindia.com/include/images/clear.gifSub Total

21849243

73.28

http://www.bseindia.com/include/images/clear.gif(2) Foreign

 

 

Total shareholding of Promoter and Promoter Group (A)

21849243

73.28

(B) Public Shareholding

http://www.bseindia.com/include/images/clear.gif(1) Institutions

 

 

http://www.bseindia.com/include/images/clear.gifMutual Funds / UTI

7998

0.03

http://www.bseindia.com/include/images/clear.gifFinancial Institutions / Banks

1332

0.00

http://www.bseindia.com/include/images/clear.gifSub Total

9330

0.03

http://www.bseindia.com/include/images/clear.gif(2) Non-Institutions

 

 

http://www.bseindia.com/include/images/clear.gifBodies Corporate

1850358

6.21

http://www.bseindia.com/include/images/clear.gifIndividuals

 

 

http://www.bseindia.com/include/images/clear.gifIndividual shareholders holding nominal share capital up to Rs. 0.100 Millions

2534067

8.50

http://www.bseindia.com/include/images/clear.gifIndividual shareholders holding nominal share capital in excess of Rs. 0.100 Millions

3342178

11.21

http://www.bseindia.com/include/images/clear.gifAny Others (Specify)

231124

0.78

http://www.bseindia.com/include/images/clear.gifClearing Members

143914

0.48

http://www.bseindia.com/include/images/clear.gifNon Resident Indians

79945

0.27

http://www.bseindia.com/include/images/clear.gifTrusts

2200

0.01

http://www.bseindia.com/include/images/clear.gifDirectors & their Relatives & Friends

5065

0.02

http://www.bseindia.com/include/images/clear.gifSub Total

7957727

26.69

Total Public shareholding (B)

7967057

26.72

Total (A)+(B)

29816300

100.00

(C) Shares held by Custodians and against which Depository Receipts have been issued

 

 

http://www.bseindia.com/include/images/clear.gif(1) Promoter and Promoter Group

0

0.00

http://www.bseindia.com/include/images/clear.gif(2) Public

0

0.00

http://www.bseindia.com/include/images/clear.gifSub Total

0

0.00

Total (A)+(B)+(C)

29816300

100.00

 

 

 

Shareholding of securities (including shares, warrants, convertible securities) of persons belonging to the category Promoter and Promoter Group

 

Sl. No.

Name of the Shareholder

Details of Shares held

Encumbered shares (*)

No. of Shares held

As a % of grand total (A)+(B)+(C)

No

As a percentage

As a % of
grand total
(A)+(B)+(C) of sub-clause (I)(a)

1

Rajratan Exports Pvt Ltd

66,66,665

22.36

4593332

68.90

15.41

2

Parenteral Commercial Services Pvt Ltd

30,986

0.10

30986

100.00

0.10

3

PDPL Holdings Pvt Ltd

32,17,120

10.79

3217120

100.00

10.79

4

PDPL Securities Pvt Ltd

6,11,506

2.05

611506

100.00

2.05

5

Mahaganpati Investments Pvt Ltd

16,00,000

5.37

850000

53.13

2.85

6

MVG Merchantile Pvt Ltd

97,22,966

32.61

5773497

59.38

19.36

 

Total

2,18,49,243

73.28

15076441

69.00

50.56

 

Shareholding of securities (including shares, warrants, convertible securities) of persons belonging to the category Public and holding more than 1% of the total number of shares

 

Sl. No.

Name of the Shareholder

No. of Shares held

Shares as % of Total No. of Shares

1

Madhukar Sheth

450585

1.51

2

Kadayam Ramnathan Bharat

519555

1.74

3

Mavi Investment Fund Ltd

300000

1.01

 

Total

1270140

4.26

 

 

BUSINESS DETAILS

 

Line of Business :

Subject is Involved in research, production and manufacturing of pharmaceutical products like intravenous infusion, tablets, capsules, liquids syrups, injections etc.

 

 

Products :

Not Divulged

 

 

Brand Names :

Not Divulged

 

 

Agencies Held :

Not Divulged

 

 

Exports :

Not Divulged

 

 

Imports :

Not Divulged

 

 

Terms :

 

Selling :

Not Divulged

 

 

Purchasing :

Not Divulged

 

 

PRODUCTION STATUS: Not Available

 

 

GENERAL INFORMATION

 

Suppliers :

Reference :

Not Divulged

Name of the Person :

Not Divulged

Contact No.:

Not Divulged

Since How Long Known :

Not Divulged

Experience :

Not Divulged

Maximum Limit Dealt :

Not Divulged

 

 

Customers :

Reference :

Not Divulged

Name of the Person :

Not Divulged

Contact No.:

Not Divulged

Since How Long Known :

Not Divulged

Experience :

Not Divulged

Maximum Limit Dealt :

Not Divulged

 

 

No. of Employees :

Information declined by the management.

 

 

Bankers :

  • State Bank of India
  • Punjab National Bank

 

 

Facilities :

SECURED LOANS

31.03.2014

(Rs. in Millions)

31.03.2013

(Rs. in Millions)

LONG TERM BORROWINGS

 

 

From Banks

 

 

Term Loans/FITL/WCTL

2583.129

2412.461

Corporate Loans

530.000

579.800

SHORT TERM BORROWINGS

 

 

From Banks

 

 

Working Capital Loans repayable on demand

682.277

502.568

Total

3795.406

3494.829

 

Note:

 

LONG TERM BORROWINGS

 

  1. Nature of security is as under:-
  1. Term Loans of Rs. 2769.547 Millions ( Rs. 2412.896, Millions), together with current maturities of Rs. 186.418 Millions (Nil) shown in note no. 8, are secured by first pari passu charge on entire fixed assets of the Company and second pari passu charge on entire current assets of the Company and first pari passu charge by way of equitable mortage of property belonging to Diamond Crystal Private Limited situated at Nemawar Road, Indore and euitable mortgage of office property belong to Parenteral Medicines Limited situated at Andheri (W) Mumbai and mortgage of house property belongs to Shri Manoharlal Gupta and Shri Vinod Kumar Gupta and first exclusive charge by way of pledge of fixed deposit and first pari passu charge by way of pledge of total 1,38,76,441 nos of equity shares of M/s. Parenteral Drugs (India) Limited held in the name of Rajratan Exports Private Limited (33,93,332), MVG Mercantile Private Limited (57,73,497), PDPL Holdings Pvt. Ltd (32,17,120), PDPL Securities Private Limited (6,11,506), Mahaganpati Investment Private Limited (8,50,000) and Parenteral Commercial Services Private Limited (30,986) and personal guarantee of four Directors, Smt. Alpana Gupta, HUF of Shri Manoharlal Gupta, Shri Vinod Gupta and Shri G.D. Garg, and Corporate Guarantee of Diamond Crystal Private Limited, Parenteral Medicines Limited, Rajratan Exports Private Limited, MVG Mercantile Private Limited, PDPL Holdings Private Limited, PDPL Securities. Private Limited, Mahaganpati Investment Private Limited, and Parenteral Commercial Services Private Limited.

Term Loans are bearing interest @ 11% to 15.25% p.a.

 

  1. Corporate Loans of Rs. 579.800 Millions (Rs. 279.825 Millions), together with current maturities of Rs. 49.800 Millions (Nil) shown in note no. 8, are secured by first pari passu charge on entire fixed assets of the Company and second pari passu charge on entire current assets of the Company and first pari passu charge by way of equitable mortage of property belonging to Diamond Crystal Private Limited situated at Nemawar Road, Indore and euitable mortgage of office property belong to Parenteral Medicines Limited situated at Andheri (W) Mumbai and mortgage of house property belongs to Shri Manoharlal Gupta and Shri Vinod Kumar Gupta and first exclusive charge by way of pledge of fixed deposit and first pari passu charge by way of pledge of total 1,38,76,441 nos of equity shares of M/s. Parenteral Drugs (India) Limited held in the name of Rajratan Exports Private Limited (33,93,332), MVG Mercantile Private Limited (57,73,497), PDPL Holdings Private Limited (32,17,120), PDPL Securities Private Limited (6,11,506), Mahaganpati Investment Pvt. Ltd (8,50,000) and Parenteral Commercial Services Private Limited (30,986) and personal guarantee of four Directors, Smt. Alpana Gupta, HUF of Shri Manoharlal Gupta, Shri Vinod Gupta and Shri G.D. Garg, and Corporate Guarantee of Diamond Crystal Private Limited, Parenteral Medicines Limited, Rajratan Exports Private Limited, MVG Mercantile Private Limited, PDPL Holdings Private Limited, PDPL Securities. Private Limited, Mahaganpati Investment Private Limited, and Parenteral Commercial Services Private Limited.

Corporate Loans are bearing interest @ 14.20% to 14.75% p.a.

 

  1. FITL/TL/WCTL includes Rs. 0.978Millions (Rs. 0.435 Millions) as interest due

Repayment schedule of Term loans,Corporate loans, FITL and WCTL is as under:-

Rs. In Millions

Payable able in 2015-16

264.760

Payable from 2016-17 to 2017-18

760.000

Payable from 2018-19 to 2019-20

960.000

Payable from 2020-21 to 2021-22

1128.369

(In Repayment of FITL includes interest on TL/CL/WCTL up to 31-03-2014)

 

SHORT TERM BORROWINGS

 

Terms of Working Capital Loan are as under:

 

Working Capital Loans of Rs. 682.277 Millions ( Rs. 50,2.568 Millions) bearing interest rate @ 16.45% to 17.00% p.a. are secured by first pari passu charge on entire current assets of the Company and second pari passu charge on entire fixed assets of the Company and first pari passu charge by way of equitable mortage of property belonging to Diamond Crystal Private Limited situated at Nemawar Road, Indore and equitable mortgage of office property belong to Parenteral Medicines Limited situated at Andheri (W) Mumbai and mortgage of house property belongs to Shri Manoharlal Gupta and Shri Vinod Kumar Gupta and first exclusive charge by way of pledge of fixed deposit and first pari passu charge by way of pledge of total 1,38,76,441 nos of equity shares of M/s. Parenteral Drugs (India) Limited held in the name of Rajratan Exports Private Limited (33,93,332), MVG Mercantile Private Limited (57,73,497), PDPL Holdings Private Limited (32,17,120), PDPL Securities Private Limited (6,11,506), Mahaganpati Investment Pvt. Ltd (8,50,000) and Parenteral Commercial Services Private Limited (30,986) and personal guarantee of four Directors, Smt. Alpana Gupta, HUF of Shri Manoharlal Gupta, Shri Vinod Gupta and Shri G.D. Garg, and Corporate Guarantee of Diamond Crystal Private Limited, Parenteral Medicines Limited, Rajratan Exports Private Limited, MVG Mercantile Private Limited, PDPL Holdings Private Limited, PDPL Securities. Private Limited, Mahaganpati Investment Private Limited, and Parenteral Commercial Services Private Limited.

 

Financial facilities are on consortium basis and State Bank of India, Commercial Branch, Indore and Punjab National Bank, Sector 16D, Chandigarh are the members.

 

 

 

Auditors :

 

Name :

T.N. Unni and Company

Chartered Accountants 

Address :

402, Alankar Point, Geeta Bhawan Square, Indore – 452 001, Madhya Pradesh, India

 

 

Memberships :

Not Divulged

 

 

Collaborators :

Not Divulged

 

 

Subsidiary Companies:

 

  • Parenteral Biotehch Limited
  • Abhay Drugs Limited
  • Parenteral Impex Limited
  • Anjaney Pharmaceuticals Limited
  • Parentech Healthcare Limited
  • Parenteral Surgicals Limited
  • Punjab Formulations Limited
  • Goa Formulations Limited
  • Mascareignes Pharmaceuticals Manufacturing Company Limited
  • Parenteral Drugs Kazakhstan

 

 

Enterprises over which Key Managerial Personnel exercise significant influence

  • Anitas Exports Private Limited
  • Parenteral Medicines Limited
  • Mahaganpati Investments Private Limited

 

 

 

CAPITAL STRUCTURE

 

As on 31.03.2014

 

Authorised Capital :

No. of Shares

Type

Value

Amount

36500000

Equity Shares

Rs.10/- each

Rs.365.000 millions

3500000

Redeemable, Non Cumulative, Non convertible Preference Shares

Rs.10/- each

Rs.35.000 million

2962102

0% Optionally convertible, redeemable Preference Shares

Rs.10/- each

Rs.29.621 millions

7037898

Redeemable Preference Shares

Rs.10/- each

Rs.70.379 millions

 

Total

 

Rs. 500.000 millions

 

Issued, Subscribed & Paid-up Capital :

No. of Shares

Type

Value

Amount

 

 

 

 

29816300

Equity Shares

Rs.10/- each

Rs. 298.163 Millions

3500000

Redeemable, Non Cumulative, Non convertible Preference Shares

Rs.10/- each

Rs. 35.000 Millions

7037898

Redeemable Preference Shares

Rs.10/- each

Rs. 70.379 Millions

 

Total

 

Rs. 403.542 Millions

 

 

Particulars

 

Number of Shares

a. Reconciliation of Shares outstanding at the beginning and at the end of the year

 

Equity Shares:-

 

At the Beginning of the year

25866831

Issued during the year (conversion of preference shares)

3949469

Outstanding at the end of the year

29816300

 

 

Preference shares

 

Redeemable, Non Cumulative, Non Convertible preference shares:-

 

At the Beginning of the year

3500000

Issued during the year

--

Outstanding at the end of the year

3500000

 

 

0% Redeemable preference shares:-

 

At the Beginning of the year

7037898

Issued during the year (conversion of preference shares)

--

Outstanding at the end of the year

7037898

 

 

0% Optionally convertible, redeemable preference shares

 

At the Beginning of the year

2962102

Converted in Equity Shares during the year

2962102

Outstanding at the end of the year

--

 

b. Terms / Rights Attached to Shares

 

Equity Shares

 

The Company has only one class of equity shares having a par value of Rs. 10/-each. Each holder of equity share is entitled to one vote per shares. The Company declares and pays dividends in Indian rupees. The dividend proposed by the Board of Directors is subject to the approval of the shareholders in the ensuing Annual General Meeting.

 

In the event of liquidation of the Company, the holders of equity shares will be entitled to receive any of the remaining assets of the company, after distribution of all preferential amounts. The distribution will be in proportion to the number of equity shares held by the shareholders.

 

Preference Shares

 

1,05,37,898 (1,05,37,898) 0% Redeemable Preference Shares are carries a 0% dividend right & can be redeemed within a period of twenty years. 29,62,102 0% Optionally convertible redeemable preference shares are converted during the year in equity shares. 39,49,469 equity shares were issued to preference shareholders which includes 9,87,367 shares issued as bonus shares as per terms.

 

 

Particulars

 

Number of Shares

c. Name of Shareholders hold more than 5% of Shares

 

Equity Shares:-

 

Rajratan Exports Private Limited

6666665

22.36%

PDPL Holding Private Limited

3217120

10.79%

Mahaganpati Investments Private Limited

1600000

5.37%

MVG Mercantile Private Limited

9722966

32.61%

 

 

Redeemable preference shares:-

 

PDPL Holding Private Limited

3500000

33.21%

Mahaganpati Investments Private Limited

7037898

66.79%

Mahaganpati Investments Private Limited (Partly paid)

--

 

 

0% Optionally convertible, redeemable preference shares:-

 

MVG Mercantile Private Limited

--

 

 

d. Detail of Shares allotted in last five years in each class other than value received in cash

 

Equity Shares

 

- Shares issued pursuant to scheme of amalgamation sanctioned by High court

4330123

- Bonus Shares Issued by capitalisation of general reserve

12066708

- Conversion preference shares which are issued pursuant to scheme of amalgamation sanctioned by High court

3949469

 

 

0% Optionally convertible, redeemable preference shares

 

Shares issued pursuant to scheme of amalgamation sanctioned by High court

--


 

FINANCIAL DATA

[all figures are in Rupees Millions]

 

ABRIDGED BALANCE SHEET

 

SOURCES OF FUNDS

31.03.2014

31.03.2013

31.03.2012

 

 

 

 

I.              EQUITY AND LIABILITIES

 

 

 

(1)Shareholders' Funds

 

 

 

(a) Share Capital

403.542

377.409

323.289

(b) Reserves & Surplus

1194.689

1708.035

2281.855

(c) Money received against share warrants

0.000

0.000

0.000

 

 

 

 

(2) Share Application money pending allotment

0.000

0.000

282.267

Total Shareholders’ Funds (1) + (2)

1598.231

2085.444

2887.411

 

 

 

 

(3) Non-Current Liabilities

 

 

 

(a) long-term borrowings

3269.743

3055.390

1495.175

(b) Deferred tax liabilities (Net)

274.505

237.751

202.797

(c) Other long term liabilities

0.000

0.000

0.000

(d) long-term provisions

0.000

0.000

0.000

Total Non-current Liabilities (3)

3544.248

3293.141

1697.972

 

 

 

 

(4) Current Liabilities

 

 

 

(a) Short term borrowings

682.277

502.568

1209.665

(b) Trade payables

293.600

392.725

614.255

(c) Other current liabilities

277.093

10.506

12.419

(d) Short-term provisions

68.069

39.802

36.180

Total Current Liabilities (4)

1321.039

945.601

1872.519

 

 

 

 

TOTAL

6463.518

6324.186

6457.902

 

 

 

 

II.          ASSETS

 

 

 

(1) Non-current assets

 

 

 

(a) Fixed Assets

 

 

 

(i) Tangible assets

3203.915

3284.114

3382.517

(ii) Intangible Assets

0.000

0.000

0.000

(iii) Capital work-in-progress

0.000

0.000

0.428

(iv) Intangible assets under development

0.000

0.000

0.000

(b) Non-current Investments

1396.407

1396.407

1396.407

(c) Deferred tax assets (net)

0.000

0.000

0.000

(d)  Long-term Loan and Advances

99.993

239.739

261.279

(e) Other Non-current assets

0.064

0.063

0.064

Total Non-Current Assets

4700.379

4920.323

5040.695

 

 

 

 

(2) Current assets

 

 

 

(a) Current investments

0.000

0.000

0.000

(b) Inventories

447.563

362.668

536.388

(c) Trade receivables

1146.841

776.297

681.527

(d) Cash and cash equivalents

56.981

53.093

73.209

(e) Short-term loans and advances

91.768

189.824

104.582

(f) Other current assets

19.986

21.981

21.501

Total Current Assets

1763.139

1403.863

1417.207

 

 

 

 

TOTAL

6463.518

6324.186

6457.902

 

 

PROFIT & LOSS ACCOUNT

 

 

PARTICULARS

31.03.2014

31.03.2013

31.03.2012

 

SALES

 

 

 

 

Income

1865.054

1872.155

2225.608

 

Other Income

571.115

1.374

2.765

 

TOTAL (A)

2436.169

1873.529

2228.373

 

 

 

 

 

Less

EXPENSES

 

 

 

 

Cost of Materials Consumed

1058.292

992.816

905.385

 

Purchases of Stock-in-Trade

9.212

9.004

164.307

 

Changes in inventories of finished goods, work-in-progress and Stock-in-Trade

(12.067)

172.037

73.962

 

Employees benefits expense

215.491

173.649

198.785

 

Other expenses

996.116

747.394

797.606

 

TOTAL (B)

2267.044

2094.900

2140.045

 

 

 

 

 

Less

PROFIT/ (LOSS)  BEFORE INTEREST, TAX, DEPRECIATION AND AMORTISATION (C)

169.125

(221.371)

88.328

 

 

 

 

 

Less

FINANCIAL EXPENSES (D)

542.419

422.244

391.901

 

 

 

 

 

 

PROFIT / (LOSS) BEFORE TAX, DEPRECIATION AND AMORTISATION (C-D) (E)

(373.294)

(643.615)

(303.573)

 

 

 

 

 

Less/ Add

DEPRECIATION/ AMORTISATION (F)

176.964

173.384

128.443

 

 

 

 

 

 

PROFIT/ (LOSS)  BEFORE TAX (E-F)   (G)

(550.258)

(816.999)

(432.016)

 

 

 

 

 

Less

TAX (H)

36.754

34.954

46.143

 

 

 

 

 

 

PROFIT/ (LOSS)  AFTER TAX  (G-H)   (I)

(587.012)

(851.953)

(478.159)

 

 

 

 

 

Add

PREVIOUS YEARS’ BALANCE BROUGHT FORWARD  (J)

(748.541)

103.412

581.571

 

 

 

 

 

 

Balance Carried to the B/S (I+J)

(1335.553)

(748.541)

(103.412)

 

 

 

 

 

 

EARNINGS IN FOREIGN CURRENCY

 

 

 

 

F.O.B. Value of Exports

194.776

125.338

90.200

 

TOTAL EARNINGS

194.776

125.338

90.200

 

 

 

 

 

 

IMPORTS

 

 

 

 

Raw Materials

151.209

103.476

162.951

 

Components and Stores parts

0.107

0.000

0.000

 

Capital Goods

0.000

4.566

0.000

 

TOTAL IMPORTS

151.316

108.042

162.951

 

 

 

 

 

 

Earnings / (Loss) Per Share (Rs.)

(19.69)

(32.94)

(18.49)

 

 

KEY RATIOS

 

PARTICULARS

 

31.03.2014

31.03.2013

31.03.2012

 

 

 

 

Net Profit Margin

(PAT / Sales)

(%)

(31.47)

(45.51)

(21.48)

 

 

 

 

 

Operating Profit Margin

(PBDIT/Sales)

(%)

9.07

(11.82)

3.97

 

 

 

 

 

Return on Total Assets

(PBT/Total Assets}

(%)

(10.86)

(16.58)

(8.54)

 

 

 

 

 

Return on Investment (ROI)

(PBT/Networth)

 

(0.34)

(0.39)

(0.15)

 

 

 

 

 

Debt Equity Ratio

(Total Debt /Networth)

 

2.47

1.71

0.94

 

 

 

 

 

Current Ratio

(Current Asset/Current Liability)

 

1.33

1.48

0.76

 

 

FINANCIAL ANALYSIS

[all figures are in Rupees Millions]

 

DEBT EQUITY RATIO

 

Particular

31.03.2012

31.03.2013

31.03.2014

 

(Rs. In Millions)

(Rs. In Millions)

(Rs. In Millions)

Share Capital

323.289

377.409

403.542

Reserves & Surplus

2281.855

1708.035

1194.689

Share Application money pending allotment

282.267

0.000

0.000

Net worth

2887.411

2085.444

1598.231

 

 

 

 

long-term borrowings

1495.175

3055.390

3269.743

Short term borrowings

1209.665

502.568

682.277

Total borrowings

2704.840

3557.958

3952.020

Debt/Equity ratio

0.937

1.706

2.473

 

 

 

YEAR-ON-YEAR GROWTH

 

Year on Year Growth

31.03.2012

31.03.2013

31.03.2014

 

(Rs. In Millions)

(Rs. In Millions)

(Rs. In Millions)

Sales

2225.608

1872.155

1865.054

 

 

(15.881)

(0.379)

 

 

 

NET PROFIT MARGIN

 

Net Profit Margin

31.03.2012

31.03.2013

31.03.2014

 

(Rs. In Millions)

(Rs. In Millions)

(Rs. In Millions)

Sales

2225.608

1872.155

1865.054

Profit

(478.159)

(851.953)

(587.012)

 

(21.48%)

(45.51%)

(31.47%)

 

 

 

LOCAL AGENCY FURTHER INFORMATION

CURRENT MATURITIES OF LONG TERM DEBTS

 

Particulars

31.03.2014

(Rs. In Millions)

31.03.2013

(Rs. In Millions)

Current maturities of long term debt

236.219

1.057

Total

236.219

1.057

 

 

Sr. No.

Check List by Info Agents

Available in Report (Yes / No)

1]

Year of Establishment

Yes

2]

Locality of the firm

Yes

3]

Constitutions of the firm

Yes

4]

Premises details

No

5]

Type of Business

Yes

6]

Line of Business

Yes

7]

Promoter's background

No

8]

No. of employees

No

9]

Name of person contacted

Yes

10]

Designation of contact person

Yes

11]

Turnover of firm for last three years

Yes

12]

Profitability for last three years

Yes

13]

Reasons for variation <> 20%

No

14]

Estimation for coming financial year

Yes

15]

Capital in the business

Yes

16]

Details of sister concerns

Yes

17]

Major suppliers

No

18]

Major customers

No

19]

Payments terms

No

20]

Export / Import details (if applicable)

No

21]

Market information

----------------------

22]

Litigations that the firm / promoter involved in

Yes

23]

Banking Details

Yes

24]

Banking facility details

Yes

25]

Conduct of the banking account

----------------------

26]

Buyer visit details

----------------------

27]

Financials, if provided

Yes

28]

Incorporation details, if applicable

Yes

29]

Last accounts filed at ROC

Yes

30]

Major Shareholders, if available

Yes

31]

Date of Birth of Proprietor/Partner/Director, if available

No

32]

PAN of Proprietor/Partner/Director, if available

No

33]

Voter ID No of Proprietor/Partner/Director, if available

No

34]

External Agency Rating, if available

Yes

 

 

LITIGATION DETAILS

 

LITIGATION DETAILS

                                                        Bench:- Bombay

Lodging No:-

SJL/449/2010

Failing Date:-

04.12.2010

Reg. No.:-

SJ/449/2010

Reg. Date:-

04.12.2010

Lodging No:-

SSL/2216/2010

Reg.No.:-

SS/2280/2010

 

Petitioner:-

EMPIRE INDUSTRIES LIMITED

Respondent:-

PERENTERAL DRUGS (INDIA) LIMITED

Petn.Adv:-

TEJPAL AND COMPANY (0)

District:-

MUMBAI

Bench:-

SINGLE

Category:-

SUMMONSES FOR JUDGEMENT

Status:-

Transffred

Stage:-

TRANSFFERED TO THE CITY CIVIL COURT

Last Date:-

01.10.2012

Act:-

Code of Civil Procedure 1908

 

 

PERFORMANCE REVIEW

 

The consolidated turnover for the year was Rs. 3344.600 Millions as compared to Rs. 3276.700 Millions in the previous year. The turnover on standalone basis stood Rs. 2436.100 Millions as against Rs. 1873.500 Millions in the previous year.

 

On consolidated basis, the Company recorded a loss before interest, depreciation and tax of Rs. 151.600 Millions during the year as against a loss of Rs 137.700 Millions in the previous year and recorded a loss before tax of Rs. 465.600 Millions during the year as against a loss of Rs. 926.200 Millions during the previous year.

 

On standalone basis, the Company recorded a profit before interest, depreciation and tax of Rs. 169.100 Millions during the year as against loss before interest, depreciation and tax of Rs. 221.300 Millions in the previous year and recorded a loss before tax of Rs. 550.200 Millions during the year as against a loss of Rs. 816.900 Millions during the previous year. The loss was on account of increase in input cost and extending extra heavy discounts to the customers to sustain in the adverse liquidity crisis conditions.

 

 

MANAGEMENT DISCUSSION AND ANALYSIS REPORT

 

OUTLOOK

 

In a world that is striving to achieve lower drug costs at every level, production costs will continue to remain a key measure. The company has a good foundation of reliable sourcing and cost effective manufacturing systems and is exploring further ways of reducing costs and strengthening competitiveness. This trend, as in the past, is expected to continue with several new launches as well as improving the existing business.

 

The Company has an enviable product basket with a large portfolio of regulatory approvals. The focus will be to continue to step up the volumes of high value products, improve the reach in the market while taking care to reduce overall costs. The Company will capitalize on its inherent strengths, some of which are given below:

  • Cost effective vertically integrated manufacturing systems;
  • Current Good Manufacturing Practices;
  • Best-in-class, best-in-cost, large manufacturing capacity;
  • Highly skilled professionals with regulatory expertise and competent to deliver on development, product processes and regulatory standards;
  • Access to new technologies.

REVIEW OF FINANCIAL PERFORMANCE WITH RESPECT TO OPERATIONAL PERFORMANCE

 

During the financial year 2013-2014, the Company met its fund requirements through a combination of short term debt and long term debt. As on 31st March, 2014, the Company earned Rs.1865.053 Millions as revenue from operations, profit before depreciation interest and tax of Rs.169.124 Millions and recorded loss after tax of Rs. 587.012 Millions.

 

The Company is continuing its focus for enhancing production capacities, optimizing output, improving margins through innovative product development, better product mix and emphasis on branded products and control on cost. Significant measures have been taken for simplification of processes and structures which will result in improvement in productivity and efficiency across the organization

 

 

UNSECURED LOANS

 

PARTICULAR

31.03.2014

(Rs. in Millions)

31.03.2013

(Rs. in Millions)

LONG TERM BORROWINGS

 

 

Security Deposit from Suppliers and Customers

152.519

59.149

Loans and Advances From Related Parties

4.095

3.980

Total

156.614

63.129

 

 

VIEW INDEX OF CHARGES

 

S. No.

Charge ID

Date of Charge Creation/Modification

Charge amount secured

Charge Holder

Address

Service Request Number (SRN)

1

10399402

21/12/2012

565,000,000.00

PUNJAB NATIONAL BANK

B.O SECTOR 16-D, CHANDIGARH, PUNJAB - 160016, INDIA

B66612870

2

10253033

23/10/2010

127,900,000.00

STATE BANK OF INDIA

COMMERCIAL BRANCH, A.B. ROAD, NEAR G.P.O., INDOR 
E, MADHYA PRADESH - 452001, INDIA

A98819212

3

10223861

21/12/2012 *

5,800,000.00

PUNJAB NATIONAL BANK

BO SECTOR 16-D, CHANDIGARH, PUNJAB - 160016, INDIA

B66611567

4

10223790

21/12/2012 *

152,800,000.00

STATE BANK OF INDIA

COMMERCIAL BRANCH, A.B. ROAD, NEAR G.P.O., INDOR 
E, MADHYA PRADESH - 452001, INDIA

B66237660

5

10071776

21/12/2012 *

7,600,000.00

PUNJAB NATIONAL BANK

BO SECTOR 16-D, CHANDIGARH, PUNJAB - 160016, INDIA

B66611690

6

10010213

21/12/2012 *

280,000,000.00

PUNJAB NATIONAL BANK

B.O. SECTOR 16-D, CHANDIGARH, PUNJAB - 160016, INDIA

B66610411

7

80023738

21/12/2012 *

2,633,000,000.00

STATE BANK OF INDIA

COMMERCIAL BRANCH, A.B. ROAD, NEAR G.P.O., INDOR 
E, MADHYA PRADESH - 452001, INDIA

B66237967

8

80007490

21/12/2012 *

875,000,000.00

STATE BANK OF INDIA

COMMERCIAL BRANCH, A.B. ROAD, NEAR G.P.O., INDOR 
E, MADHYA PRADESH - 452001, INDIA

B66238171

* Date of charge modification

 

 

CONTINGENT LIABILITIES:

 

 i) Claim against the company not acknowledged as debt-

-Certain show-causes notices adjudicated by the Central excise department. The challenged demand under the notices is Rs. 27.440 Millions (Rs. 23.021 Millions) which is pending before H'ble CESTAT.

 

-Show cause notices issued by Excise Department amounting to Rs. 184.913 Millions (Nil) which are quashed by H'ble High Court of Indore. Department has preferred an appeal in the H'ble Supreme Court which is pending.

 

-One demand under Entry Tax Act for Rs. 16.554 Millions (16.554 Millions) for which the Company has filed writ petition in the High Court of Madhya Pradesh Bench at Indore and demand is stayed by the H'ble High Court.

 

-One demand for penalty under Entry Tax Act for Rs. 38.788 Millions (Nil) for which the Company has filed appeal before Commissioner (Appeal) Indore and demand is stayed by the Commissioner (Appeal).

 

-Three Income Tax demands of Rs. 10.049 Millions (Rs. 10.049 Millions) were raised by Assessing Officer, which are not admitted and rectification/appeals are pending before the relevant authorities.

 

-Three demand for sales tax of Rs. 0.864 Millions (Nil) were raised by Commercial Tax Officer, for which the Company has filed appeal before Deputy Commissioner (Appeal), Jalandhar.

 

-One demand under DPCO Act for Rs. 1.931 Millions (1.931 Millions) for which the Company has filed writ petition in the High Court of M.P. and demand is stayed by the H'ble High Court.

 

ii) Bank Guarantees: Rs. 21.766 Millions (Rs. 27.215 Millions)

 

iii) Other contingent liabilities

-Eight group companies have offered collateral securities (1) by mortgage of two companies immovable properties and (2) by pledge of shares in favour of the Company against credit facilities and corporate loan by six companies.

Amount involved was uncertain.

-Corporate Guarantee given to one subsidiary company to the tune of Rs. 127.9,00 Millions (Rs. 1035.400  Millions).

-Sacrifice of lenders under approved CDR scheme of Rs. 28.124 Millions (28.124 Millions).

 

 

STATEMENT OF STANDALONE UNAUDITED FINNNCIAL RESULTS FOR THE QUARTER HALF YEAR ENDED 30TH SEPTEMBER 2014

 

Sr.

No.

Particular

 

Three Months Ended

Half Year Ended

 

 

30.09.2014

30.06.2014

30.09.2014

 

 

(Unaudited)

(Unaudited)

(Unaudited)

 

 

 

 

 

1.

Net Sales/Income from Operations

474.631

528.793

1003.424

 

Other Operating Income

0.205

0.284

0.489

 

Total Income From Operations (Net)

474.836

529.077

1003.913

 

 

 

 

 

2.

Expenditure

 

 

 

 

Cost of materials consumed

268.502

281.589

550.091

 

Purchase of stock in trade

0.000

0.000

0.000

 

Changes in inventories of finished goods, work in progress and stock in trade

(36.881)

19.450

(17.431)

 

Employee benefits expenses

44.448

46.357

90.805

 

Depreciation and amortization expenses

44.212

44.212

88.424

 

Other expenses

171.523

161.953

333.476

 

Total Expenses

491.804

553.561

1045.365

 

 

 

 

 

3.

Profit From Operations before Other Income, Interest and Exceptional Items (1-2)

(16.968)

(24.485)

(41.453)

 

 

 

 

 

4.

Other Income

0.000

0.000

0.000

 

 

 

 

 

5.

Profit Before Interest and Exceptional Items (3+4)

(16.968)

(24.485)

(41.453)

 

 

 

 

 

6.

Interest/Finance Cost

146.793

142.103

288.896

 

 

 

 

 

7.

Profit After Interest but before Exceptional Items (5-6)

(163.761)

(166.588)

(330.349)

 

 

 

 

 

8.

Exceptional Items

0.000

0.000

0.000

 

 

 

 

 

9.

Profit from Ordinary Activities before Tax (7+8)

(163.761)

(166.588)

(330.349)

 

 

 

 

 

10.

Tax Expense

9.189

9.189

18.378

 

 

 

 

 

11.

Net Profit from Ordinary Activities after Tax (9-10)

(172.950)

(175.777)

(348.727)

 

 

 

 

 

12.

Extraordinary Item (net of expense)

0.000

0.000

0.000

 

 

 

 

 

13.

Net Profit for the period (11-12)

(172.950)

(175.777)

(348.727)

 

 

 

 

 

14.

Paid-up Equity Share Capital (Face Value of Rs.10/- Each)

298.163

298.163

298.163

 

 

 

 

 

15.

Reserves Excluding Revaluation Reserve

0.000

0.000

0.000

 

 

 

 

 

16.

Basic and Diluted Earning Per Share (EPS) (Rs.)-Not Annualised

 

 

 

 

a) Basic and diluted EPS before extraordinary items

(5.80)

(5.90)

(11.70)

 

b) Basic and diluted EPS after extraordinary items

(5.80)

(5.90)

(11.70)

 

 

 

 

 

17.

Public Shareholding

 

 

 

 

-Number of Shares

7967057

7967057

7967057

 

- Percentage of Shareholding

26.72%

26.72%

26.72%

 

 

 

 

 

18.

Promoters and Promoter Group Shareholding

 

 

 

 

a) Pledged/Encumbered

 

 

 

 

- Number of Shares

15076441

15076441

15076441

 

- Percentage of Shares (as a % of the Total Shareholding of promoter and promoter group)

69.00%

69.00%

69.00%

 

- Percentage of Shares (as a % of the Total Share Capital of the Company)

50.56%

50.56%

50.56%

 

 

 

 

 

 

b) Non Encumbered

 

 

 

 

- Number of Shares

6772802

6772802

6772802

 

- Percentage of Shares (as a % of the Total Shareholding of Promoter and Promoter Group)

31.00%

31.00%

31.00%

 

- Percentage of Shares (as a % of the Total Share Capital of the Company)

22.72%

22.72%

22.72%

 

B

INVESTOR COMPLAINTS

3 Months ended (30.09.2014)

 

Pending at the beginning of the quarter

0

 

Received during the quarter

0

 

Disposed of during the quarter

0

 

Remaining unresolved at the end of the quarter

0

 

 

 

 

 

 

STANDALONE STATEMENT OF ASSETS AND LIABILITIES

 

Particulars

As at 30.09.2014

 

Particulars

 

A

EQUITY AND LIABILITIES

 

1

Shareholder’s Funds

 

 

a) Share Capital

403.542

 

b) Reserves & Surplus

845.961

 

Sub Total- Shareholders funds

1249.503

2

Share application money pending allotment

0.000

3

Minority Interest

0.000

4

Non-current liabilities

 

 

(a) Long term borrowings

3359.555

 

(b) Other long term liabilities

292.883

 

Sub Total- Non Current Liabilities

3652.438

5

Current liabilities

 

 

(a) Short term borrowings

814.529

 

(b) Trade Payables

312.225

 

(c) Other current liabilities

360.167

 

(d) Short term provisions

58.589

 

Sub Total- Current Liabilities

1545.510

 

TOTAL-EQUITY AND LIABILITIES

6447.451

B

ASSETS

 

1

Non-current assets

 

 

(a) Fixed assets

3127.886

 

(b) Non-current Investments

1396.407

 

(c) Long term loans and advances

88.270

 

(d) Other Non-current assets

0.064

 

Sub-Total- Non current assets

4612.627

2

Current assets

 

 

a) Current Investments

0.000

 

b) Inventories

516.242

 

c) Trade Receivables

1237.429

 

d) Cash and cash equivalents

30.657

 

(e) Short term loans and advances

31.836

 

(f) Other current assets

18.660

 

Sub-Total- current assets

1834.824

 

TOTAL ASSETS

6447.451

 

Note:

 

The above results were reviewed by statutory auditors and audit committee of the company on 13th November 2014 and approved by Board of Directors in their meeting held on 14th November, 2014.


The Company is engaged in the Pharmaceuticals business only and therefore, there is only one reportable segment in accordance with the Accounting Standard on Segment Accounting (AS-17).


The previous year/period have been regrouped/rearranged wherever found necessary.

 

FIXED ASSETS

 

·         Land

·         Building

·         Plant and Equipment

·         Furniture and Fixtures

·         Vehicles

·         Office Equipments

·         Computer

·         Computer and Software

 

 

 


CMT REPORT (Corruption, Money Laundering & Terrorism]

 

The Public Notice information has been collected from various sources including but not limited to: The Courts, India Prisons Service, Interpol, etc.

 

1]         INFORMATION ON DESIGNATED PARTY

No exist designating subject or any of its beneficial owners, controlling shareholders or senior officers as terrorist or terrorist organization or whom notice had been received that all financial transactions involving their assets have been blocked or convicted, found guilty or against whom a judgement or order had been entered in a proceedings for violating money-laundering, anti-corruption or bribery or international economic or anti-terrorism sanction laws or whose assets were seized, blocked, frozen or ordered forfeited for violation of money laundering or international anti-terrorism laws.

 

2]         Court Declaration :

No records exist to suggest that subject is or was the subject of any formal or informal allegations, prosecutions or other official proceeding for making any prohibited payments or other improper payments to government officials for engaging in prohibited transactions or with designated parties.

 

3]         Asset Declaration :

No records exist to suggest that the property or assets of the subject are derived from criminal conduct or a prohibited transaction.

 

4]         Record on Financial Crime :

            Charges or conviction registered against subject:                                                                       None

 

5]         Records on Violation of Anti-Corruption Laws :

            Charges or investigation registered against subject:                                                        None

 

6]         Records on Int’l Anti-Money Laundering Laws/Standards :

            Charges or investigation registered against subject:                                                        None

 

7]         Criminal Records

No available information exist that suggest that subject or any of its principals have been formally charged or convicted by a competent governmental authority for any financial crime or under any formal investigation by a competent government authority for any violation of anti-corruption laws or international anti-money laundering laws or standard.

 

8]         Affiliation with Government :

No record exists to suggest that any director or indirect owners, controlling shareholders, director, officer or employee of the company is a government official or a family member or close business associate of a Government official.

 

9]         Compensation Package :

Our market survey revealed that the amount of compensation sought by the subject is fair and reasonable and comparable to compensation paid to others for similar services.

 

10]        Press Report :

            No press reports / filings exists on the subject.

 


 

CORPORATE GOVERNANCE

 

MIRA INFORM as part of its Due Diligence do provide comments on Corporate Governance to identify management and governance. These factors often have been predictive and in some cases have created vulnerabilities to credit deterioration.

 

Our Governance Assessment focuses principally on the interactions between a company’s management, its Board of Directors, Shareholders and other financial stakeholders.

 

 

CONTRAVENTION

 

Subject is not known to have contravened any existing local laws, regulations or policies that prohibit, restrict or otherwise affect the terms and conditions that could be included in the agreement with the subject.

 

 

FOREIGN EXCHANGE RATES

 

Currency

Unit

Indian Rupees

US Dollar

1

Rs. 62.16

UK Pound

1

Rs. 94.27

Euro

1

Rs. 73.73

 

 

INFORMATION DETAILS

 

Information Gathered by :

NYA

 

 

Analysis Done by :

RAS

 

 

Report Prepared by :

TRU


 

SCORE & RATING EXPLANATIONS

 

SCORE FACTORS

 

RANGE

POINTS

HISTORY

1~10

4

PAID-UP CAPITAL

1~10

3

OPERATING SCALE

1~10

4

FINANCIAL CONDITION

 

 

--BUSINESS SCALE

1~10

4

--PROFITABILITY

1~10

2

--LIQUIDITY

1~10

3

--LEVERAGE

1~10

3

--RESERVES

1~10

4

--CREDIT LINES

1~10

3

--MARGINS

-5~5

--

DEMERIT POINTS

 

 

--BANK CHARGES

YES/NO

YES

--LITIGATION

YES/NO

YES

--OTHER ADVERSE INFORMATION

YES/NO

NO

MERIT POINTS

 

 

--SOLE DISTRIBUTORSHIP

YES/NO

NO

--EXPORT ACTIVITIES

YES/NO

NO

--AFFILIATION

YES/NO

YES

--LISTED

YES/NO

YES

--OTHER MERIT FACTORS

YES/NO

YES

DEFAULTER

 

 

--RBI

YES/NO

NO

--EPF

YES/NO

NO

TOTAL

 

30

 

This score serves as a reference to assess SC’s credit risk and to set the amount of credit to be extended. It is calculated from a composite of weighted scores obtained from each of the major sections of this report. The assessed factors and their relative weights (as indicated through %) are as follows:

 

Financial condition (40%)            Ownership background (20%)                  Payment record (10%)

Credit history (10%)                   Market trend (10%)                                Operational size (10%)

 


 

RATING EXPLANATIONS

 

 

RATING

STATUS

 

 

PROPOSED CREDIT LINE

>86

Aaa

Possesses an extremely sound financial base with the strongest capability for timely payment of interest and principal sums

 

Unlimited

71-85

Aa

Possesses adequate working capital. No caution needed for credit transaction. It has above average (strong) capability for payment of interest and principal sums

 

Large

56-70

A

Financial & operational base are regarded healthy. General unfavourable factors will not cause fatal effect. Satisfactory capability for payment of interest and principal sums

 

Fairly Large

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

 

Satisfactory

26-40

B

Capability to overcome financial difficulties seems comparatively below average.

 

Small

11-25

Ca

Adverse factors are apparent. Repayment of interest and principal sums in default or expected to be in default upon maturity

 

Limited with full security

<10

C

Absolute credit risk exists. Caution needed to be exercised

 

 

Credit not recommended

--

NB

                                       New Business

 

--

 

PRIVATE & CONFIDENTIAL : This information is provided to you at your request, you having employed MIPL for such purpose. You will use the information as aid only in determining the propriety of giving credit and generally as an aid to your business and for no other purpose. You will hold the information in strict confidence, and shall not reveal it or make it known to the subject persons, firms or corporations or to any other. MIPL does not warrant the correctness of the information as you hold it free of any liability whatsoever. You will be liable to and indemnify MIPL for any loss, damage or expense, occasioned by your breach or non observance of any one, or more of these conditions

This report is issued at your request without any risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL) or its officials.